Lancet Neuro:鼻喷催产素或可改善额颞叶痴呆患者的淡漠症状

2025-05-26 MedSci原创 MedSci原创 发表于上海

这项突破性研究为额颞叶痴呆这一难治性疾病提供了首个经临床验证的治疗选择。

额颞叶痴呆患者常表现出严重的淡漠症状,目前临床上缺乏有效治疗方法。一项跨国研究发现,每三天使用一次鼻喷催产素(72IU)可以安全有效地改善这类患者的淡漠症状。这项名为FOXY的2a/2b期临床试验由加拿大和美国11个专业医疗中心共同完成,为额颞叶痴呆的治疗带来了新希望。该研究创新性地采用适应性临床试验设计,通过两阶段研究精准确定了最佳给药方案,相关成果已发表在《柳叶刀·神经病学》期刊。

研究采用创新的两阶段适应性交叉设计。第一阶段纳入了60名30-80岁的额颞叶痴呆患者,随机分配至每天、隔天或每三天使用一次催产素或安慰剂组。研究人员特别关注了患者神经精神量表淡漠评分的变化,同时通过脑功能成像监测催产素对边缘系统脑区的影响。经过6周治疗后,贝叶斯分析显示每三天使用一次的方案效果最佳。第二阶段随即招募34名新患者,专门验证这一最优方案。最终结果显示,与安慰剂相比,每三天使用催产素可使神经精神量表淡漠评分平均降低1.32分,具有统计学意义。

特别值得注意的是,这种治疗方案表现出良好的安全性。在94名参与者中,仅报告了上呼吸道感染和头痛等轻微不良反应,且发生率与安慰剂组相当。研究采用严格的双盲设计,所有治疗套装外观完全相同,确保评估结果的客观性。脑部影像学数据显示,催产素能特异性激活与情感调节相关的脑区,这可能是其改善淡漠症状的神经机制。这种给药方案的另一优势是使用便捷,患者只需在家自行鼻腔给药,大大提高了治疗依从性。

尽管治疗效果显著,研究人员也指出改善幅度相对有限。这可能与催产素分子在鼻腔吸收后难以有效穿透血脑屏障有关。研究团队负责人表示:"虽然1.32分的改善看似不大,但对长期处于情感淡漠状态的患者而言,任何细微的改善都能显著提升生活质量。"未来研究将探索更高效的制剂配方,或尝试间歇性给药方案以增强疗效。同时,团队计划开展更大规模的3期临床试验,进一步验证长期治疗效果,并评估其对患者日常生活能力和照顾者负担的影响。

这项突破性研究为额颞叶痴呆这一难治性疾病提供了首个经临床验证的治疗选择。虽然目前效果尚属温和,但为后续研发指明了方向。对患者家属而言,这种非药物治疗方案操作简单、副作用小,为日常照护提供了新选择。

原始出处:

Finger EC. Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial. Lancet Neurol. 2025 Feb;24(2):128-139.

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2266779, encodeId=681a2266e7970, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 26 23:11:13 CST 2025, time=2025-05-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2266785, encodeId=64642266e8528, content=研究创新性地采用适应性临床试验设计,通过两阶段研究精准确定了最佳给药方案,相关成果已发表在《柳叶刀·神经病学》期刊。, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb76152142, createdName=baiwenxiu_6586, createdTime=Tue May 27 00:09:07 CST 2025, time=2025-05-27, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2266783, encodeId=9b902266e83bb, content=额颞叶痴呆患者常表现出严重的淡漠症状,目前临床上缺乏有效治疗方法。一项跨国研究发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79c89675194, createdName=ms7000001603885209, createdTime=Mon May 26 23:38:06 CST 2025, time=2025-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2266695, encodeId=cb8a22666957f, content=<a href='/topic/show?id=c0df103411f8' target=_blank style='color:#2F92EE;'>#鼻内喷雾#</a> <a href='/topic/show?id=061f1123e01b' target=_blank style='color:#2F92EE;'>#淡漠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=112370, encryptionId=061f1123e01b, topicName=淡漠), TopicDto(id=103411, encryptionId=c0df103411f8, topicName=鼻内喷雾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Mon May 26 11:58:56 CST 2025, time=2025-05-26, status=1, ipAttribution=上海)]
    2025-05-26 1209e435m98(暂无昵称) 来自浙江省

    学习了,谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2266779, encodeId=681a2266e7970, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 26 23:11:13 CST 2025, time=2025-05-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2266785, encodeId=64642266e8528, content=研究创新性地采用适应性临床试验设计,通过两阶段研究精准确定了最佳给药方案,相关成果已发表在《柳叶刀·神经病学》期刊。, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb76152142, createdName=baiwenxiu_6586, createdTime=Tue May 27 00:09:07 CST 2025, time=2025-05-27, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2266783, encodeId=9b902266e83bb, content=额颞叶痴呆患者常表现出严重的淡漠症状,目前临床上缺乏有效治疗方法。一项跨国研究发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79c89675194, createdName=ms7000001603885209, createdTime=Mon May 26 23:38:06 CST 2025, time=2025-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2266695, encodeId=cb8a22666957f, content=<a href='/topic/show?id=c0df103411f8' target=_blank style='color:#2F92EE;'>#鼻内喷雾#</a> <a href='/topic/show?id=061f1123e01b' target=_blank style='color:#2F92EE;'>#淡漠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=112370, encryptionId=061f1123e01b, topicName=淡漠), TopicDto(id=103411, encryptionId=c0df103411f8, topicName=鼻内喷雾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Mon May 26 11:58:56 CST 2025, time=2025-05-26, status=1, ipAttribution=上海)]
    2025-05-27 baiwenxiu_6586 来自山西省

    研究创新性地采用适应性临床试验设计,通过两阶段研究精准确定了最佳给药方案,相关成果已发表在《柳叶刀·神经病学》期刊。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2266779, encodeId=681a2266e7970, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 26 23:11:13 CST 2025, time=2025-05-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2266785, encodeId=64642266e8528, content=研究创新性地采用适应性临床试验设计,通过两阶段研究精准确定了最佳给药方案,相关成果已发表在《柳叶刀·神经病学》期刊。, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb76152142, createdName=baiwenxiu_6586, createdTime=Tue May 27 00:09:07 CST 2025, time=2025-05-27, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2266783, encodeId=9b902266e83bb, content=额颞叶痴呆患者常表现出严重的淡漠症状,目前临床上缺乏有效治疗方法。一项跨国研究发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79c89675194, createdName=ms7000001603885209, createdTime=Mon May 26 23:38:06 CST 2025, time=2025-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2266695, encodeId=cb8a22666957f, content=<a href='/topic/show?id=c0df103411f8' target=_blank style='color:#2F92EE;'>#鼻内喷雾#</a> <a href='/topic/show?id=061f1123e01b' target=_blank style='color:#2F92EE;'>#淡漠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=112370, encryptionId=061f1123e01b, topicName=淡漠), TopicDto(id=103411, encryptionId=c0df103411f8, topicName=鼻内喷雾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Mon May 26 11:58:56 CST 2025, time=2025-05-26, status=1, ipAttribution=上海)]
    2025-05-26 ms7000001603885209

    额颞叶痴呆患者常表现出严重的淡漠症状,目前临床上缺乏有效治疗方法。一项跨国研究发现

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2266779, encodeId=681a2266e7970, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon May 26 23:11:13 CST 2025, time=2025-05-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2266785, encodeId=64642266e8528, content=研究创新性地采用适应性临床试验设计,通过两阶段研究精准确定了最佳给药方案,相关成果已发表在《柳叶刀·神经病学》期刊。, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb76152142, createdName=baiwenxiu_6586, createdTime=Tue May 27 00:09:07 CST 2025, time=2025-05-27, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2266783, encodeId=9b902266e83bb, content=额颞叶痴呆患者常表现出严重的淡漠症状,目前临床上缺乏有效治疗方法。一项跨国研究发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79c89675194, createdName=ms7000001603885209, createdTime=Mon May 26 23:38:06 CST 2025, time=2025-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2266695, encodeId=cb8a22666957f, content=<a href='/topic/show?id=c0df103411f8' target=_blank style='color:#2F92EE;'>#鼻内喷雾#</a> <a href='/topic/show?id=061f1123e01b' target=_blank style='color:#2F92EE;'>#淡漠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=112370, encryptionId=061f1123e01b, topicName=淡漠), TopicDto(id=103411, encryptionId=c0df103411f8, topicName=鼻内喷雾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Mon May 26 11:58:56 CST 2025, time=2025-05-26, status=1, ipAttribution=上海)]
    2025-05-26 梅斯管理员 来自上海

相关资讯

J Endod:鼻内3%丁卡因加0.05%羟甲唑啉(Kovanaze)对上颌磨牙的麻醉效果

非注射式麻醉是常规麻醉给药途径的一种有希望的替代产品。这篇研究的目的是为了评估患者的优先选择性以及3%丁卡因加0.05%羟甲唑啉(Kovanaze)鼻内喷雾麻醉对上颌侧切牙和第一前磨牙的麻醉效果。

拓展阅读

J Endod:鼻内3%丁卡因加0.05%羟甲唑啉(Kovanaze)对上颌磨牙的麻醉效果

非注射式麻醉是常规麻醉给药途径的一种有希望的替代产品。这篇研究的目的是为了评估患者的优先选择性以及3%丁卡因加0.05%羟甲唑啉(Kovanaze)鼻内喷雾麻醉对上颌侧切牙和第一前磨牙的麻醉效果。